Camzyos
Payments companies reported to CMS as associated with Camzyos. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Camzyos, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Camzyos
These are the largest totals companies reported as associated with Camzyos. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Richard Wright | Santa Monica, CA | Advanced Heart Failure and Transplant Cardiology | $338,561.35 |
| Dipanjan Banerjee | Honolulu, HI | Cardiovascular Disease | $210,476.36 |
| David Hinchman | Boise, ID | Cardiovascular Disease | $182,069.69 |
| Robert Biederman | Charleston, SC | Cardiovascular Disease | $180,183.31 |
| Mariko Harper | Seattle, WA | Cardiovascular Disease | $178,529.53 |
| Benjamin Kalsmith | Pgh, PA | Cardiovascular Disease | $171,351.93 |
| Jesal Popat | Tampa, FL | Interventional Cardiology | $169,391.73 |
| Robby Wu | Tampa, FL | Cardiovascular Disease | $157,433.49 |
| Mark Zenker | Nashville, TN | Cardiovascular Disease | $146,641.74 |
| Shepard Weiner | New York, NY | Cardiovascular Disease | $119,336.57 |
Prescribed Camzyos?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.